Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
The primary hypothesis in this trial is that the treatment with vericiguat 10 mg or 15 mg in
patients with HFpEF improves the KCCQ PLS (Kansas City Cardiomyopathy Questionnaire Physical
limitation score) compared to placebo after 24 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Collaborators:
Canadian VIGOUR Centre Duke Clinical Research Institute Merck Sharp & Dohme Corp.